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Role of microRNAs, circRNAs and long
noncoding RNAs in acute myeloid leukemia
Yan Liu1,2,3, Zhiheng Cheng4, Yifan Pang5, Longzhen Cui2, Tingting Qian1,3, Liang Quan1,3, Hongyou Zhao6,
Jinlong Shi7, Xiaoyan Ke8 and Lin Fu1,3,9*
Abstract
Acute myeloid leukemia (AML) is a malignant tumor of the immature myeloid hematopoietic cells in the bone
marrow (BM). It is a highly heterogeneous disease, with rising morbidity and mortality in older patients. Although
researches over the past decades have improved our understanding of AML, its pathogenesis has not yet been fully
elucidated. Long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs) are three
noncoding RNA (ncRNA) molecules that regulate DNA transcription and translation. With the development of RNA-
Seq technology, more and more ncRNAs that are closely related to AML leukemogenesis have been discovered.
Numerous studies have found that these ncRNAs play an important role in leukemia cell proliferation,
differentiation, and apoptosis. Some may potentially be used as prognostic biomarkers. In this systematic review, we
briefly described the characteristics and molecular functions of three groups of ncRNAs, including lncRNAs, miRNAs,
and circRNAs, and discussed their relationships with AML in detail.
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Background
Acute myeloid leukemia (AML) is an aggressive
hematological malignancy characterized by abnormal
proliferation and differentiation of the immature myeloid
cells [1]. Despite a growing list of treatment options,
most patients still relapse and die after remission, and
the prognosis remains unideal [2]. It is necessary to ex-
plore new biomarkers for diagnosis, prognostication, and
therapeutic targets of AML so as to develop more effect-
ive surveillance and treatment programs.
The discovery of noncoding RNAs (ncRNAs) opens up
new prospects for AML diagnosis, prognosis and treat-
ment. ncRNAs are functional small RNA molecules that
are not translated into a protein [3]. The DNA mole-
cules that make up the human genome are about 3 bil-
lion base pairs, of which about 5–10% are stably
transcribed, but protein-coding genes account for less
than 2% of the human genome. The remaining 3–8% of
the genome are transcribed into non-coding transcripts,
i.e., ncRNAs [4–6]. ncRNAs are divided into two cat-
egories based on their functions: housekeeping and regu-
latory, the latter includes miRNAs, circRNAs, and
lncRNAs. Regulatory ncRNAs are extensively involved in
gene transcription and translation. They are key players
in physiological and pathological processes such as cell
differentiation, ontogenesis, inflammation, and angiogen-
esis. There is emerging evidence that miRNAs, cir-
cRNAs, and lncRNAs actively participate in the
pathogenesis of major hematological malignancies in-
cluding AML [7]. In this review, we aimed to provide a
comprehensive summary of the roles of miRNAs, cir-
cRNAs, and lncRNAs in AML, and to illustrate their
diagnostic and prognosticating potentials in this disease.
MicroRNA
MicroRNAs (miRNAs) are small RNA molecules of ap-
proximately 22 nucleotides that bind to the 3′-untrans-
lated region (3′-UTR) of the target mRNA and
negatively regulate the expression of the target gene at
the transcriptional level [8]. miRNAs mainly participate
in the pathogenesis of AML through the following five
mechanisms: copy number alterations, change in the
proximity to the oncogenic genomic region due to
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chromosomal translocation, epigenetic changes, aberrant
targeting of miRNA promoter regions by altered tran-
scription factors or oncoproteins, and finally, dysregu-
lated miRNAs processing [9].
Abnormal miRNA expression and function in acute
myeloid leukemia
The molecular and cytogenetic criteria currently defined
by 2016 WHO is the most widely used diagnostic tool
for AML [10]. Each AML subtype seems to exhibit a
unique miRNA signature that distinguishes it from
others. For example, Chen et al. reported miR-9, an
oncogenic miRNA, was overexpressed in the mixed
lineage leukemia (MLL)-rearranged AML patients. In-
hibition of miR-9 expression could significantly reduce
cell growth/viability and promote apoptosis [11]. Emm-
rich et al. found miR-9, significantly downregulated in
pediatric AML with t(8;21), was characterized by its
tumor-suppressive property. Upregulation of miR-9 de-
creased leukemic growth and induced monocytic differ-
entiation of t(8;21) AML cell lines in vitro and in vivo.
Functionally, miR-9 exerted its effects by binding to
let-7 to suppress the oncogenic LIN28B/HMGA2 axis
[12]. In another study, miR-9-1 was observed to be
downregulated in t(8;21) AML. Besides, overexpressed
miR-9-1 induced differentiation and inhibited prolifera-
tion in t(8;21) AML cell lines [13]. MiR-10a/b was sig-
nificantly increased in AML patients with t(8;21), t(9;11),
NPM1 mutation, and particularly M1, M2, and M3 sub-
type. Abnormal high expression in those patients led to
unlimited proliferation of immature blood progenitors
and repressed differentiation and maturation of mature
blood cell [14]. Another study showed that miR-10a
overexpression was significantly associated with
French-American-British(FAB)-M3/t(15;17) subtypes
and NPM1 mutation, leading to the lower percentage of
bone marrow (BM) blasts, while overexpression of
miR-10b was correlated with NPM1 and DNMT3A mu-
tations, resulting in higher percentage of BM blasts [15].
Some studies observed overexpression of the miR-181 in
cytogenetic normal AML (CN-AML) patients with
CEBPA mutations, FLT3-ITD, and/or wild-type NPM1
and t(15;17) [16–19]. MiR-155 was upregulated in
FLT3-ITD-associated AML and targeted the myeloid
transcription factor PU.1. Knockdown of miR-155 could
repress proliferation and induce apoptosis of FLT3-IT-
D-associated leukemic cells [20].
MiRNA expression is also associated with morphologic
sub-types of AML. MiR-122 expression, as an oncogene,
was decreased in BM samples from pediatric patients
with FAB subtype M7, and the forced expression of
miR-122 in AML cell lines significantly inhibited cell
proliferation and reduced the ratio of S-phase cells [21].
Xu et al. recently reported higher expression of
miR-196b was observed in pediatric AML with M4/5
subtypes and predicted a poor outcome [22]. Another
study compared M1 with M5 samples and noted that ex-
pressions of miR-146a/b, miR-181a/b/d, miR-130a,
miR-663, and miR-135b were higher in M1, whereas ex-
pressions of miR-21, miR-193a, and miR-370 were
higher in M5 [23]. Interestingly, in normal BM,
miR-181a was enriched in B cells, T cells, monocytes,
and granulocytes [24], but its overexpression was less
common in monocytic lineage AML subtypes M4 or
M5, but more so in M1 or M2 subtypes [25]. The ex-
pression levels of miR-195 in both BM and serum were
significantly decreased, and pediatric patients with low
serum miR-195 level more often had FAB-M7, unfavor-
able karyotypes, and shorter relapse-free and overall sur-
vival (OS) [26].
Changes in miRNA expression levels alter the expressions
of downstream genes, promoting AML leukemogenesis
[27]. For example, miR-155, acting as an oncogenic
miRNA, may participate in the pathogenesis of AML by
targeting SHIP1 and downregulating transcription factor
PU.1 expression [28, 29]. This miRNA was regulated by
NF-κB, whose activity was partly controlled by the
NEDD8-dependent ubiquitin ligases [30, 31]. Schneider et
al. reported that miR-155 expression was positively corre-
lated with Meis1 expression level in MLL-rearranged AML
and first indicated that the transforming efficacy ofMLL-fu-
sions remained unaltered in the absence of miR-155, while
knocking out miR-155 did not affect in vitro leukemia for-
mation or progression [32]. Other studies demonstrated
that miR-9/9* was aberrantly expressed in myeloid pro-
genitors of most AML cases to inhibit neutrophil differ-
entiation by regulating EGN post-transcriptional level.
Moreover, miR-9 could promote proliferation of
leukemia cells in adult CD34+ AML with normal karyo-
type by suppressing Hes1 expression and knockdown of
miR-9 could reduce circulating leukemic cell counts in
peripheral blood (PB) and BM, attenuate splenomegaly
and prolong survival in a xenotransplant mouse model
[33, 34]. Li et al. showed that miR-193a expression was
downregulated in AML1/ETO-positive leukemia cells
because AML1/ETO triggered the heterochromatic si-
lencing of miR-193a by binding at AML1-binding sites
and recruiting chromatin-remodeling enzymes. Then
the epigenetic silencing of tumor suppressor gene
miR-193a led to leukemogenesis in AML with t(8;21)
by activating the PTEN/PI3K signal pathway [35]. The
latest study found that Erbin was the target of
miR-183-5p that negatively regulated the Erbin expres-
sion, resulting in enhanced cell proliferation of AML
cells via activation of RAS/RAF/MEK/ERK and PI3K/
AKT/FoxO3a pathways [36]. MiR-125b, as an onco-
genic miRNA, frequently overexpressed in human
AML, could promote MLL-AF9-driven murine AML by
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TET2-VEGFA pathway. Zhang et al. reported that
miR-203 downregulation frequently occurred in CD34 +
AML cells in relation to CD34− cells isolated from pa-
tients. Additionally, re-expression of miR-203 inhibited
cell proliferation, self-renewal, and sphere formation in
LSCs by targeting survivin and Bmi-1 [37].
MicroRNAs are associated with chemoresistance of AML
Chemoresistance is commonly seen in refractory and re-
current AML. Studies have shown that miRNAs are in-
volved in AML chemotherapy resistance in many ways,
such as apoptosis, cell cycle and ATP-binding cassette
(ABC) transporter-mediated multidrug resistance.
Li et al. reported that miR-181a expression level was
lower in the K562/A02 cells than in the K562 cells and
could reduce doxorubicin resistance of K562/A02 cells
by directly targeting the 3′-UTR of BCL-2 and MCL-1
mRNAs [38]. Similarly, miR-181a was underexpressed in
the HL-60/Ara-C cell line compared with HL-60 cell
line, while upregulated miR-181a in HL-60/Ara-C cells
sensitized the cells to Ara-C treatment and promoted
apoptosis by releasing cytochrome C and activating cas-
pase-9/caspase-3 pathway. Functionally, BCL-2 was con-
firmed as a direct miR-181a target [39]. MiR-182-5p
expression levels were higher in blood samples of AML
patients than the normal samples. Cellular function indi-
cated miR-182-5p inhibition in AML cells could de-
crease cell proliferation, promote AML cell apoptosis,
and reverse cisplatin (DDP) resistance via targeting
BCL2L12 and BCL2 expression [40].
Clinical chemotherapy drugs mainly interfere with cell
cycle by inhibiting cellular DNA and RNA synthesis.
FoxM1, an established oncogenic factor promoting cell
cycle progression, plays a role in this process. MiR-370
expression was decreased in both leukemia cell lines
(K562 and HL-60) and primary leukemic cells from pa-
tients BM with de novo AML. Ectopic expression of
miR-370 in HL60 and K562 cells arrested cell growth
and led senescence, while knockout of miR-370 expres-
sion promoted the proliferation of those leukemic cells.
Mechanistically, miR-370 played a tumor suppressive
role by targeting FoxM1. Moreover, when AML cells
were treated with 5-aza-2′-deoxycytidine (a DNA
methylation inhibitor), upregulation of miR-370 expres-
sion was observed, suggesting epigenetic silencing of
miR-370 in leukemic cells [41]. Cyclin D1 is a target pro-
tein of PTEN signaling pathway. PTEN mainly negatively
regulates PI3K/AKT pathway through lipid phosphatase
activity, then degrades Cyclin D1, leading to cell cycle
organization in G1 phase. MiR-21 may desensitize
leukemia cells to chemotherapy by interfering PTEN ex-
pression. Bai et al. reported high miR-21 expression in
daunorubicin (DNR) resistant cell line K562/DNR.
K562/DNR cell line stable transfected with miR-21
inhibitor was induced drug resistance, while inhibition
of miR-21 enhanced cell sensitivity to cytotoxicity. Drug
resistance mechanism of miR-21 was associated with
regulating PTEN protein expression [42].
Chemotherapy drug resistance is also associated with
efflux of hydrophobic drugs out of cells. ABC trans-
porter and P-glycoprotein (P-gp), encoded by the MDR1
gene, play pivotal roles in this process [43, 44]. MiR-381
and miR-495 were strongly underexpressed in K562/
ADM cells. Restoring expression of miR-381 or miR-495
reduced expression of the MDR1 gene and its protein
product P-gp, and increased drug uptake via targeting the
3′-UTR of the MDR1 gene [45]. In the drug-resistant cell
line HL-60/VCR, miR-138 was significantly downregu-
lated. Enhanced miR-138 expression significantly down-
regulated P-gp expression level and MRP1 transcription to
promote doxorubicin-induced apoptosis and reversed
HL-60/VCR resistance to P-gp dependent and P-gp inde-
pendent to drug delivery [46]. Besides, Feng et al. found
that the expression of miR-331-5p and miR-27a was nega-
tively correlated withMDR1 expression, and the upregula-
tion of miR-331-5p and miR-27a decreased MDR1
expression and increased the sensitivity of K562-resistant
cell line to doxorubicin [47].
MicroRNAs and DNA methylation
Aberrant DNA methylation is an important epigenetic
modification in the pathogenesis of AML. DNA methyl-
transferases are mainly divided into two types: DNMT1
and DNMT3. The former maintains methylation, and
the latter performs de novo methylation [48]. Garzon et
al. demonstrated that miR-29b directly targeted
DNMT3A and DNMT3B and indirectly targeted
DNMT1, leading to DNA hypomethylation and tumor
suppressor gene reactivation [49]. The indirect inhibition
of DNMT1 was mediated by a zinc finger-like structural
transcription factor SP1, which bound directly to the
DNMT1 promoter region to start transcription [50].
MiR-29b downregulates SP1 expression, thereby disrupt-
ing SP1-dependent DNMT1 transcription [11]. Another
example of DNMTs inhibition was hypomethylating
tumor suppressor P115INK4b which could reduce sus-
ceptibility to myeloid leukemia in mouse model [51].
Phase 2 data of decitabine in elderly AML patients con-
firmed that miR-29b upregulation in BM cells could re-
duce the expression of DNMTs, enhance the effect of
DNA hypomethylating agents, and therefore improve
the remission rate [52].
MiR-29b could, however, be downregulated by SP1, as
well as KIT. KIT overexpression has been observed in
various tumors, including AML, and it promotes malig-
nant cell proliferation [53]. Liu et al. identified that
aberrant activation of KIT resulted in decreased MYC-
dependent miR-29b expression and increased SP1
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expression, the latter then interacted with the NF-κB/
HDAC complex to further inhibit miR-29b expression
and transactivate KIT [54].
Contrary to miR-29b, which suppressed leukemogenesis,
miR-221 was able to contribute to the aggressive nature of
AML via the NCL/miR-221/NF-κB/DNMT1 network. A
group in China designed a nanoparticle that delivered
anti-miR-221 antisense RNA in to leukemia cells. The
nanoparticle could directly reactivate tumor suppressor
gene p27Kip1 by annihilating miR-221 and upregulate
other tumor suppressor gene expressions by downregulat-
ing DNMT1. In mouse model, the nanoparticle showed
promising therapeutic outcome [55].
Gene targets of miRNA may overcome the suppression
or even downregulate the respective miRNA by DNA
hypermethylation. For example, miR-375 could suppress
HOXB3 expression and cause AML cell proliferation ar-
rest and colony reduction. In return, HOXB3 enhanced
DNMT3B’s binding to the promoter of miR-375, leading
to DNA hypermethylation and lower expression of
miR-375 [56].
The role of exosomal microRNAs in acute myeloid
leukemia
Exosomes are cell-derived, biologically active membrane-
bound vesicles. The role of exosomes in hematopoiesis is
receiving increasing attention. In 2015, Hornick et al.
identified a set of miRNAs enriched in AML exo-
somes from the NOD/SCID/IL-2rγnull (NSG) mice
serum, such as let-7a, miR-99b, miR-146a, miR-150,
miR-155, miR-191, and miR-1246. These serum exo-
somal miRNAs could potentially be used for early de-
tection of AML [57]. Barrera-Ramirez et al. later
sequenced miRNAs from exosomes isolated from
AML patients’ marrow samples and from healthy
controls. Of the five candidate miRNAs identified by
differential packaging in exosomes, miR-26a-5p and
miR-101-3p were significantly increased in AML,
while miR-23b-5p, miR-339-3p, and miR-425-5p were
significantly decreased, but the role and target genes
of these exosomal miRNAs were still unknown [58].
Some of them might be AML tumor suppressors.
Another study found that exosomes isolated from cul-
tured AML cells or AML mice plasma were enriched
with miR-150 and miR-155. Hematopoietic stem/pro-
genitor cells (HSPCs) co-cultured with either of the
two exosomes experienced impaired clonogenicity
through the miR-150- or miR-155-mediated suppres-
sion of c-MYB, a transcription factor involved in
HSPC differentiation and proliferation [59]. Moreover,
Huan et al. found that the Molm-14 exosome was
also enriched in miR-150. This exosome was respon-
sible for decreasing migration of AML cell lines and
reducing the surface expression of CXCR4 [60].
Some exosomal miRNAs may promote AML
leukemogenesis. In a recent study, miR-7977 was found
to have higher levels in AML exosomes than those from
normal CD34+ cells. It might be a critical player in
disrupting normal hematopoiesis via suppression of
poly(rC)-binding protein. It also induced aberrant pro-
duction of hematopoietic growth factors in mesenchy-
mal stem cells, resulting in a hostile microenvironment
for the normal stem cells [61].
Leukemia stem cells (LSCs) are believed to be the pri-
mary source of exosomes. Shedding harmful miRNAs
via exosomes might be a mechanism of LSCs’
self-protection. Peng et al. discovered that miR-34c-5p
was significantly downregulated in AML (excluding
APL) stem cells compared to normal HSPCs. Increased
expression of miR-34c-5p could induce LSC senescence
ex vivo via both p53-dependent and independent CKD/
Cyclin pathways. LSC could generate miR-34c-5p defi-
ciency by actively packing and transporting miR-34c-5p
out of the cells in exosomes. In return, miR-34c-5p
could suppress exosome-mediated transfer via a positive
feedback loop through RAB27B, a molecule that pro-
motes exosome shedding. By targeting RAB27B,
miR-34c-5p could enrich its intracellular level and in-
duce LSC senescence [62].
MicroRNAs as biomarkers for prognosis in acute myeloid
leukemia
miRNAs have many properties of good AML prognostic
biomarkers, such as wide presence in various tissues,
highly conserved sequences, and easy and sensitive de-
tection, as well as stability under extreme conditions [63,
64]. Mounting studies have shown that miRNAs can be
used to predict outcome in CN-AML. Zhang et al. re-
ported miR-216b overexpression as an independently
poor prognostic factor for CN-AML and may provide a
valuable biomarker associated with disease recurrence in
AML [65]. In 224 patients with CN-AML, high
miR-362-5p expression was associated with older age
and shorter OS compared with low expressers [66].
Diaz-Beya et al. reported that high miR-3151 expression
was commonly found in AML patients and obtained
shorter disease-free, OS, lower CR rate and higher cu-
mulative incidence of relapse compared with low ex-
pressers [67]. The underexpression of miR-328 in AML
patients had poor clinical outcome and may provide a
diagnostic and prognostic biomarker [68]. MiR-34a ex-
pression was negatively correlated with aggressive clin-
ical variable. Patients with low miR-34a expression
showed shorter overall and recurrence-free survival [69].
Xu et al. reported miR-135a as an independent prognos-
tic factor for outcome in AML and a tumor suppressor
in AML by inversely regulating HOXA10 expression
[70]. Moreover, patients with high expression levels of
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miR-146a and miR-3667 tended to have more favorable
prognoses than their low expression counterparts [71],
while underexpression of miR-122, miR-192, miR-193b-3p,
miR-204, and miR-217, as well as miR-340 had been well
studied to be unfavorable prognostic predictors of AML
[72–77].
Some polymorphic miRNAs only had prognostic impact
in certain subtypes. MiR-204 has two sites of variations:
one is the upstream flanking region (rs718447 A > G), and
the other is the gene itself (rs112062096 A > G). Butrym et
al. demonstrated that miR-204 rs718447 GG homozygosity
was a risk factor and associated with short survival [78].
Some miRNAs biomarkers might be helpful in select-
ing patients for allogenic hematopoietic stem cell trans-
plant (allo-HSCT). High miR-425 level was associated
with significantly longer OS and event-free survival
(EFS) in non-transplant patients, but this association
was not observed in post allo-HSCT patients. Instead,
patients with downregulated miR-425 did better if they
had allo-HSCT, suggesting that low miR-425 level might
be an indication for transplant [79]. Overexpression of
miR-99a predicted adverse prognosis in AML patients ir-
respective of transplant status, necessitating the investi-
gation of novel alternative treatment in miR-99a
overexpressors [80]. Moreover, high expression of
miR-98 correlated with good clinical outcome in AML
patients treated with chemotherapy alone [81].
miRNAs have potential prognostic value complement-
ing information gained from gene mutations. MiR-181
family, which has been associated with CEBPA muta-
tions and FLT3-ITD and/or NPM1 wild-type in
CN-AML, did demonstrate prognostic value [17]. Mar-
cucci et al. reported favorable clinical outcomes in
CN-AML patients with miR-181 overexpression and
CEBPA mutations or miR-181 overexpression with
FLT3-ITD [82]. In BM mononuclear cells of 113 de novo
AML patients, miR-19b overexpression had more fre-
quently occurred and high miR-19b expression had a
higher frequency of mutations of U2AF1 and IDH1/2
genes and associated with poor prognosis and disease re-
currence in AML [83]. AML patients with low miR-186
expression were frequently observed, and harbored
lower complete remission rate and shorter OS, while
miR-186high patients had a significantly higher frequency
of CEBPA mutation [84]. These findings suggested that
measuring miRNA may have potential advantages for
predicting prognosis of AML compared to assessed gene
mutations such as DMNT3A, FLT3-ITD, NPM1, and
CEBPA. In published studies, univariate and multivariate
analysis showed that miR-98, miR-99a, miR-340,
miR-216b, and miR-34c had independent stronger prog-
nostic impact on EFS and OS (P < 0.05) than gene muta-
tions in FLT3-ITD, NPM1, DMNT3A, RUNX1, CEBPA,
and TP53 [80, 81, 85, 86].
To summarize, miRNA researches in AML have
yielded important results. The major miRNAs and their
roles in AML were listed in Table 1.
Circular RNAs
Circular RNAs (circRNAs) are ubiquitous, stable, and
conserved non-coding RNAs. They are closed circular
RNA molecules and lack the 3′- and 5′-ends, different
from the linear RNAs [141]. This structure was first de-
scribed in viroids but later was also found in eukaryotic
cells [142]. There are four types of circRNAs, namely ex-
onic circRNAs (ecircRNAs), circRNAs from introns,
exon-intron circRNAs (EIciRNAs), and intergenic cir-
cRNAs [143].
Aberrant circRNA expression levels in acute myeloid
leukemia
With the help of sequencing technology, more than
10,000 circRNAs in human have been identified [144,
145]. Aiming to pinpoint circRNAs that correlated with
AML, Li et al. [146] used circRNAs microarray and
characterized the expression profile of circRNAs in
CN-AML, in which 147 circRNAs were upregulated and
317 circRNAs were downregulated compared with
healthy control. An interesting phenomenon was that
while hsa_circ_0004277 was one of the most signifi-
cantly downregulated circRNAs in AML, its expression
level was restored in patients who achieved complete re-
mission, and the level post-remission was the same as
healthy control, but it significantly dropped if the patient
became relapse-refractory. Their findings suggested that
hsa_circ_0004277 could be a potential diagnostic bio-
marker in detecting early relapse. Another circRNA,
circPVT1, was overexpressed in AML harboring onco-
gene MYC amplification [147], and this association
could hint that circPVT1 might impact the survival of
AML patients.
In vitro and in vivo experiments have confirmed that
the fusion circRNAs are derived from a fusion gene pro-
duced by chromosomal translocation. The study by
Guarnerio et al. discovered PML/RARα-derivative
f-circPR, and MLL/AF9-derivative f-circM9, and both
promoted malignant transformation, chemoresistance,
and leukemia cell survival [148]. AML1 transcription
factor complex is the most common target for
leukemia-associated chromosomal translocations. HIPK2
is part of the AML1 complex and activates AML1-me-
diated transcription. Li et al. screened mutations of the
HIPK2 gene in 50 cases of AML and found two missense
mutations (R868W and N958I) of HIPK2 that are local-
ized to nuclear regions with conical or ring shapes [149].
Hirsch et al. detected circular RNAs of NPM1. They
found that the circular NPM1 transcript, i.e., has_-
circ_0075001, had lower expression in healthy volunteers
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Table 1 miRNAs in acute myeloid leukemia
miRNAs Genetic abnormalities Altered expression Targets Function Reference
miR-9 t(8;21)(q22;q22.1) RUNX1-
RUNX1T1; mutated NPM1;
biallelic mutations of CEBPA
↑in MLL-rearranged AML RHOH
RYBP
miR-9 was upregulated by MLL-AF9 and in-
creased MLL-AF9-mediated cell transformation
in murine hematopoietic progenitor cells in
vitro and in vivo. Mice transplanted with BM
progenitors that overexpressed both MLL-AF9
and miR-9 (MLL-AF9+ miR-9) had higher fre-
quency of c-Kit+ blast cells in the BM, spleen,
and peripheral blood than MLL-AF9 mice.
Moreover, MLL-AF9+ miR-9 leukemic cells had
a higher frequency of immature blasts
[11]
↓in t(8;21) AML HMGA2
LIN28B







RUNX1-RUNX1T1 triggered the heterochromic
silencing of miR-9-1, resulting in hypermethyla-
tion of the miR-9-1 promoter in t(8; 21) AML.
Silencing of miR-9-1 promoted expression of
target genes(RUNX1, RUNX1T1, and RUNX1-
RUNX1T1), which inhibited differentiation and
promoted the proliferation of t(8; 21) AML cell
lines
[13]
↑3YPERLINK \lline ERG ERG is a direct target of miR-9 which contrib-
uted to miR-9/9*-induced differentiation of
progenitor cells towards neutrophils
[33]
↑3YPERLINK \l "_ENREF_33"
\o "Nowek K, 2016 #298"
hor><Yeaparients with
normal karyotype
Hes1 miR-9 negatively regulated Hes1 expression
and knockdown of miR-9 suppressed the pro-
liferation of AML cells by the induction of G0
arrest and apoptosis in vitro, decreased circu-
lating leukemic cell counts in peripheral blood
and bone marrow, attenuated splenomegaly,
and prolonged survival in a xenotransplant
mouse model
[34]
↓in AE-positive cell lines SIRT1 Knockdown of SIRT1 expression inhibits cell
proliferation in AE-positive AML cell lines
[87]
↓in EVI1-induced AML FOXO1
FOXO3
Increase proliferation and decrease monocytic
differentiation
[88]
miR-21 Mutated NPM1; mutated
RUNX1
↑in K562/DNR PTEN Decreased cell sensitivity to daunorubicin [42]
↑in SKM-1 cell PTEN/AKT
pathway
Downregulation of miR-21 expression inhibits
proliferation and induces G1 arrest and apop-
tosis in SKM-1 cell
[89]
miR-22 ↓iR-22LINK \l " CRTC1
FLT3
MYCBP
Represses the CREB and MYC pathways [90]
miR-29b PML-RARA; mutated NPM1 ↑in K562 cells DNMT3A
DNMT3B
DNMT1
Increase DNA methylation and
hypermethylation
[49]
↓in t(8;21) AML SP1 Upregulate KIT contributing to malignant
proliferation
[54]
↓in various subtypes of AML AKT2
CCND2
Increase cell growth, leukemic progression in
vivo
[91]
↓in various subtypes of AML MCL-1
CXXC6
CDK6
Increase cell growth, decrease apoptosis,
leukemic progression in vivo
[92]
↓in various subtypes of AML SP1
DNMT3A
DNMT3B
Results in global DNA hypermethylation [93]
↑in NK cells Damage to NK cells development and
function
[94]
miR-34a Biallelic mutations of CEBPA ↓in CEBPA mutated AML E2F3 Increase proliferation and decrease
differentiation
[95]
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Table 1 miRNAs in acute myeloid leukemia (Continued)
miRNAs Genetic abnormalities Altered expression Targets Function Reference
↓in de novo AML PDL1 Immune dysregulation [96]
↓in CEBPA mutated AML cell
lines
HMGB1 Inhibit cell apoptosis and increased autophagy [97]
miR-34b ↓iR-34bINK \l "_ENREF_ CREB Survival signaling pathways [98]





High miR-99a expression could predict worse
outcome in AML patients undergoing allo-
HCST
[80]
↑in initial diagnosis and
relapse
Regulate self-renewal, inhibiting differentiation





Increase proliferation, colony formation, cell
survival, inhibite differentiation
[100]




Increase proliferation, colony formation, cell
survival
[101]




↑in MDS and AML with
t(2;11) (p21;q23)
Inhibit differentiation [103]
↑in AML LIN28A Uncontrolled generation of myeloid cells [104]
IRF4 Induce myeloid leukemia in mice by inducing
immortality, self-renewal, and tumorigenesis in
myeloid progenitors
[105]
↑in pediatric AML FES
PU.1
Block monocytic differentiation of AML in vitro [106]
↑in AML cell lines NF-κB Inhibits human AML cells invasion,





↑in t(8;21) and inv(16) AML PLK2 Inhibits cell apoptosis and increase cell viability [108]
↑in LSCs of AML Increase leukemic growth, and survival of
leukemic stem and progenitor cells in vivo
[109]
↑in t(8;21) AML ERRFI1
SPRED1
FZD7
Both gain and loss of function of miR-126 pro-
motes leukemogenesis in vivo through target-
ing distinct gene signaling
[110]
↑in LSC of CN-AML Increase LSC maintenance and self-renewal [111]
↑in LSCs of AML ADAM9, ILK,
GOLPH3,
CDK3, TOM1
Increase LSC maintenance and self-renewal,
quiescence, chemotherapy resistance in vivo
[112]
↑in AML cell lines TRAF7 Suppresses apoptosis by downregulating
TRAF7, which blocks the c-FLIP pathway
[113]
miR-135a ↓in AML HOXA10 Overexpression of miR-135a inhibits the prolif-
eration and cell cycle and promotes cellular
apoptosis
[70]
miR-139-5p ↓iR-139-5p \l "_E EIF4G2 Repressing the translation initiation, specifically
inducing the translation of cell cycle inhibitor
p27 Kip1
[114]
miR-143 ↑inCD34 + HSPCs ERK5 Increase granulocyte surface marker Ly6G and
a more mature morphology toward
granulocytes induces apoptosis
[115]





↓in del(5q) MDS TIRAP
TRAF6
Inappropriate activation of innate immune
signaling in HSPCs and megakaryocytic
abnormalities
[117]
Knockout in del(5q)MDS/AML Increase cell survival and proliferation of [118]
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Table 1 miRNAs in acute myeloid leukemia (Continued)
miRNAs Genetic abnormalities Altered expression Targets Function Reference
propagating cells through the TRAF6/p62/NF-
κB complex
IRAK1 miR-146a knockout mice develop myeloid and
lymphoid malignancies
[119]
miR-146a deletion leads to myeloproliferation
in mice
Knockout in del(5q) MDS/
AML
Co-deletion of TIFAB and miR-146a may co-
operate to induce TRAF6 signaling contribut-
ing to ineffective hematopoiesis
[120]
miR-146a/Traf6 axis controls autoimmunity and
myelopoiesis in mice
[121]
↑in elderly AML patients CXCR4
Smad4
Suppress the migration abilities of leukemia
cells and promote cell cycle entry in leukemia
cells
[122]
miR-149-5p ↑iR-149 FASLG Targeting FASLG led to suppression on cell
apoptosis
[123]
miR-150 PML-RARA ↓in various subtypes of AML NANOG Increase proliferation, colony, and sphere
formation, increase tumor growth in vivo
[124]
↓in various subtypes of AML EIF4B,
FOXO4,
PRKCA, TET3
Increase cell growth and inhibits apoptosis in




CXCR4 Decrease migration of Ba/F3 cells and the





isolated from cultured AML
cells
c-MYB Hematopoiesis is suppressed by releasing







Targeting the RAS-MAPK-pathway [126]
miR-182-5p PML-RARA; Mutated NPM1;
FLT3-ITD




Promote cell proliferation, and reverse cisplatin
(DDP) resistance
[40]
↑in APL CEBPα Induce apoptosis [127]








AML1/ETO triggers the heterochromatic
silencing of microRNA-193a (miR-193a) by
binding at AML1-binding sites and recruiting
chromatin-remodeling enzymes, which ex-
pands the oncogenic activity of AML-ETO,
resulting in leukemogenesis
[35]





Apoptosis and a G1/S-phase block [74]
miR-196b t(9;11)(p21.3;q23.3) MLLT3-
KMT2A; mutated NPM1
↑in MLL associated AML Increase proliferation and survival, and
decrease differentiation and replating potential
[129]
↑in MLL-associated AML HOXA9
Meis1
FAS
Inhibit differentiation, promote cell
proliferation, and induce leukemic progression
in mice
[130]
miR-204 Mutated NPM1 ↑in AML cells BIRC6 Lead to AML cell apoptosis [131]










Involve in DNA hypomethylation [55]
miR-223 t(8;21)(q22;q22.1) RUNX1-
RUNX1T1; CBFB-MYH1;
↓in t(8;21) AML Myeloid differentiation block [133]
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than in AML cell lines, and its expression was positively
correlated with total NPM1 expression, but not with the
status of NPM1 mutation [150]. Nevertheless, none of
the current studies have elucidated the role of circRNA
in AML pathogenesis.
The AML-related circRNAs and their roles in AML
have been summarized in Table 2.
Long noncoding RNA
Long noncoding RNAs (lncRNAs) are noncoding RNAs
that are more than 200 nucleotides in length and lack a
meaningful open reading frame [159]. lncRNAs are clas-
sified into intergenic lncRNAs, intron lncRNAs, sense
lncRNAs, and antisense lncRNAs [160]. In cells, differ-
ent lncRNAs may act as (1) a signal molecule, expressed
at specific time and in specific tissues, regulating the ex-
pression of certain genes; (2) a miRNA sponge; (3) a
leader molecule, directing RNAs that bind to
RNA-binding proteins to reach regulatory sites, and
regulating the expression of the relevant gene; and (4) a
scaffold molecule, being a central platform for the as-
sembly of other molecules.
lncRNAs involved in acute myeloid leukemia
pathogenesis
lncRNAs play an important role in BM cell differenti-
ation and are subjected to differentiation-inducing ther-
apies. HOTAIRM1 and NEAT1 are two important
examples. HOTAIRM1 is a myeloid-specific lncRNA
that is transcribed from the locus between the HOXA1
and HOXA2 genes. In the initial studies of lncRNAs in
AML, HOTAIRM1 was found to be a regulator of mye-
loid differentiation and maturation by affecting the ex-
pression levels of integrin genes such as ITGA4(CD49d)
and ITGAX(CD11c). Knocking down HOTAIRM1 would
prohibit all-trans retinoic acid (ATRA)-induced granulo-
cyte differentiation [161]. The fact that HOTAIRM1
came from the HOXA cluster might imply that it could
Table 1 miRNAs in acute myeloid leukemia (Continued)
miRNAs Genetic abnormalities Altered expression Targets Function Reference
PML_RARA; mutated NPM1;
mutated RUNX1
↓in various subtypes of AML E2F1 Lead to AML cell apoptosis [134]
↓in AML with adverse
prognosis
Impair differentiation [135]
↓in various subtypes of AML FBXW7 Increase cell proliferation and enhance
apoptosis
[136]
miR-339-5p ↓in AML cells SOX4 Inhibit cell proliferation of AML cells [137]
miR-345-5p Mutated NPM1 ↓in AML cell lines AKT1/2 Facilitate the proliferation of leukemia cells [138]
miR-370 ↓iR-370 NF1 Activation of the RAS signaling pathway [139]





Involve in DNA hypomethylation [56]
miR-7977 ↑in AML cell lines miR-7977 in extracellular vesicles may be a
critical factor that induces failure of normal






↑in exosomes derived from






↓in exosomes derived from









Enriched in exosomes from
NSG mice serum
[57]
Let-7c ↓in AML patients with t(8;21)
and inv(16)
PBX2 Promotes granulocytic differentiation [140]
Abbreviations: HSPC hematopoietic stem and progenitor cell, LSC leukemia stem cells, MSCs bone marrow mesenchymal stromal cells, NSG NOD/SCID/IL-2rγnull,
allo-HSCT allogeneic hematopoietic stem cell transplantation, PB peripheral blood, BM bone marrow
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regulate nearby genes in the HOXA cluster, although
this warranted further investigation. The other lncRNA,
NEAT1, was significantly downregulated by PML-RARα
in de novo APL samples compared with those of healthy
donors. In NB4 cells, silencing NEAT1 could block
ATRA-induced differentiation [162]. The roles of
HOTAIRM1 and NEAT1 in normal hematopoiesis and
leukemogenesis are awaiting further elucidation.
Other lncRNAs participate in regulating AML cell
proliferation, cell cycle, and apoptosis. A typical example
is lncRNA PVT1 [163]. The coding sequence of PVT1
on the chromosome is adjacent to MYC. Functional ac-
quisition of MYC and PVT1 due to amplification of
8q24.21 is observed in approximately 10% of AML pa-
tients [164]. In AML cell lines, overexpression of PVT1
could induce apoptosis and necrosis, probably through
downregulating c-MYC expression [165, 166]. UCA1 is
another lncRNA that might have the capability to modu-
late AML cell proliferation; silencing of UCA1 by short
hairpin RNA would result in a significantly slower cell
proliferation and G1 cell cycle arrest. UCA1 could pro-
mote proliferation by inhibiting the expression of the
cell cycle regulator p27kip1 [167]. Similarly, CRNDE
could coordinate the proliferation and differentiation of
AML cells as demonstrated by Wang et al. in their ex-
periment with the U937 cell line [168]. At present, most
of the lncRNA studies in AML are ex vivo, and the de-
tailed mechanisms of lncRNA regulating cell prolifera-
tion remain to be investigated.
LncRNA expression in AML with recurrent genetic
mutations
Distinct lncRNA expression patterns have been observed
in different AML subtypes, reflecting the heterogeneity
of this disease. AML is most common in older patients
(age ≥ 60) although they often have a worse prognosis
[169, 170]. Numerous studies have identified characteris-
tic lncRNA profiles in age ≥ 60 CN-AML patients with
recurrent genetic mutations such as FLT3-ITD, NPM1,
CEBPA, and RUNX1 mutations.
FLT3-ITD-related lncRNAs
Wilms’ tumor 1(WT1) expression positively correlates
with FLT3-ITD in patients with AML [171]. Benetatos et
Table 2 CircRNAs in acute myeloid leukemia
circRNAs Altered expression Targets Function Reference
f-circPR ↑in NB4 cells Promote proliferation and colony formation of leukemia cells [148]
f-circM9 ↑in THP-1 cells and K562 cells Promote proliferation and colony formation of leukemia cells;
knockout of f-circM9 increased apoptosis of THP1
[148]
hsa_circ_0075001 ↑in AML(M0 or M1)↓in AML(M2, M4
and M5)
Hsa_circ_0075001 expression relates positively to total NPM1
expression, independent of the NPM1 mutational status; high
hsa_circ_0075001 expression decreased expression of components of
the Toll-like receptor signaling pathway
[150]








Increase cell proliferation and inhibited apoptosis via interacting with
miR-203/Rab10 axis
[152]
circPAN3 ↑ircPAN3138" \o "Fan H, 2018 #193"
or>Fan H</Author><







Downregulation of circPAN3 by siRNA restores ADM sensitivity of THP-
1/ADM cells depend on miR-153-5p/miR-183-5p-XIAP axis
[153]
circ_0009910 ↑irc_000perients BM miR-
20a-5p
Promoted cell proliferation, inhibited apoptosis and predicted adverse
prognosis
[154]
circ-HIPK2 Mutation of HIPK2 in AML and MDS Impair AML1- and p53-mediated transcription
↓in APL patients PB and NB4 cells miR-
124-3p
Influence ATRA-induced differentiation of APL cells [155]
circ-DLEU2 ↓in pediatric AML-M5 Hypermethylation of DLEU2 affected prognosis [156]




Promote AML cells proliferation and inhibited cell apoptosis and AML
tumor formation in vivo via suppressing miR-496 and promoting
PRKACB expression
[157]
has_cir_0004277 ↓in mononuclear cells from AML
patients BM
Increasing level of hsa_circ_0004277 is associated with chemotherapy [158]
circPVT1 Overexpression in AML-amp Unknown [147]
Abbreviations: amp amplicons involving chromosome band 8q24, BM bone marrow, PB peripheral blood, CN-AML cytogenetically normal AML, THP-1/ADM cell
doxorubicin (ADM)-resistant THP-1 AML cell
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al. identified that lncRNA MEG3 could be activated by
WT1 and TET2 and it acted as a cofactor of WT1, en-
hancing leukemogenesis [172].
CEBPA mutation-related lncRNAs
CCAAT/enhancer-binding protein-α (CEBPA) is a crit-
ical regulator of myeloid differentiation and 10% of
AML have mutations in CEBPA, which may lead to the
expression of a 30-kDa dominant negative isoform (C/
EBPα-p30) [173]. Hughes et al. identified a C/EBPα-p30
target lncRNA UCA1. It was increased in CN-AML pa-
tients with biallelic CEBPA mutations and could pro-
mote cell proliferation [167]. Another study reported
that HOXB-AS3 was the most downregulated lncRNA in
CEBPA-mutated AML while it was upregulated in
NPM1-mutated AML [174].
NPM1 mutation-related lncRNAs
Besides the aforementioned HOXB-AS3 [175], the
coiled-coil domain containing 26 (CCD26) is also upreg-
ulated in the NPM1-mutated AML and is a retinoic
acid-dependent modulator of myeloid cell differentiation
and death [176]. Apart from them, a recent study
employing RNA-sequencing identified another NPM1
mutation-associated lncRNA XLOC_109948 whose high
expression predicted a poor prognosis [177].
RUNX1 mutation-related lncRNAs
Fernando et al. first characterized CASC15, a conserved
lncRNA upregulated in pediatric AML with RUNX1 mu-
tation. High expression of CASC15 led to myeloid-
predominant BM development, decreased engraftment,
and colony formation. Researchers also found that
CASC15 positively regulated YY1-mediated SOX4 pro-
moter [178].
Prognostic value of lncRNAs in acute myeloid leukemia
LncRNA expression level could predict AML clinical
features and outcomes. A published study has confirmed
that lncRNAs can assist to predict clinical outcome in
older patients with CN-AML. In the basic of 148
CN-older (age > 60 years) AML patients, Garzon et al.
evaluated the associations of lncRNA expression with
clinical characteristics, gene mutations, and outcome
and built a lncRNA score including 48 lncRNAs for in-
dependently outcome prognosis [179]. Li et al. reported
that SNHG5 overexpression was frequently observed in
AML patients with advanced FAB classification and un-
favorable cytogenetics. Furthermore, a higher SNHG5
expression level was also associated with shorter OS
[180]. Yang et al. have determined the PANDAR expres-
sion level and its clinical significance in 119 de novo
AML patients. AML patients expressing a higher level of
PANDAR were associated with low complete remission
rate and adverse prognosis in comparison with those
with lower expression of PANDAR [181]. Moreover, high
HOTAIR expression was associated with adverse clinical
outcomes [182]. Based on 64 de novo non-M3 AML pa-
tients, Pashaiefar et al. found that low expression of
IRAIN was independently associated with adverse prog-
nosis: higher white blood cell count and blast counts
and shorter OS and relapse-free survival. Besides, pa-
tients with refractory response to chemotherapies and
those with subsequent relapse were more likely to show
a lower initial IRAIN expression [183].
TUG1 has been in the spotlight of AML research.
Higher TUG1 expression level occurred in AML pa-
tients with monosomal karyotype, FLT3-ITD mutation,
and poor-risk and correlated with higher white blood
cell counts and worse event-free survival and overall sur-
vival [184]. Luo et al. investigated the correlation of
TUG1 expression with clinicopathological features and
its predictive value for treatment response and survival
profiles in refractory or relapsed AML patients age ≥ 60
years. They demonstrated that AML patients with higher
TUG1 expression had shorter OS, and a lower rate of
complete response and overall response than those with
lower TUG1 expression [185].
Overall, there are only a few published reports of
lncRNAs’ prognostic value in AML; thus, more pro-
found works are required to investigate the association
of lncRNAs, clinical characteristics, mutations, and out-
come. The researches on AML-related lncRNAs are
summarized in Table 3.
lncRNAs and circRNAs can interfere with miRNA
function in AML
It has recently been learned that aberrant expression of
lncRNAs and circRNAs in AML can change the function
of specific miRNAs contributing to initiation, mainten-
ance, and development of leukemogenesis.
In 2011, Salmena et al. proposed a competing en-
dogenous (ceRNA) hypothesis that lncRNAs competi-
tively binds to endogenous miRNAs in AML. A lncRNA,
H19, for example, was found overexpressed in BM sam-
ples from patients with AML-M2; it promoted AML cell
proliferation by sequestering miR-19a/b [186]. The
lncRNA NEAT1 that competitively binds miR-23a-3p,
an oncogenic miRNA, thus modulating the expression of
SMC1A in AML cells, which affected myeloid leukemia
cell proliferation and apoptosis [187]. UCA1 is a func-
tional lncRNA that promoted cell proliferation, migra-
tion, and invasion of human AML cells via binding
miR-126 [188]. In accord with Zhang et al.’s study, its
expression was abnormally upregulated following
doxorubicin-based chemotherapy and knockdown of
UCA1 helped overcome chemoresistance in pediatric
AML by suppressing glycolysis via binding miR-125a
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[189]. FTX is another lncRNA involved in chemoresis-
tance, and it controlled the expression of ALG3 by bind-
ing miR-342 [193]. HOXA cluster antisense RNA 2
(HOXA-AS2) was significantly upregulated in BM sam-
ples from AML patients after treatment with
adriamycin-based chemotherapy and sponged miR-
520c-3p to contribute to chemoresistance in AML [195].
An oncogenic activity of lncRNA was also shown by
HOTAIR that regulating the expression of c-Kit in AML
cells through competitively binding miR-193a, an im-
portant tumor-suppressor miRNA to predict a poor clin-
ical outcome [190]. HOTAIRM1, a lncRNA located in
the HOXA genomic region, is related to myeloid differ-
entiation which sequestered miR-20a, miR-106b and
Table 3 lncRNAs in acute myeloid leukemia
lncRNAs Altered expression Targets Function Reference
PVT1 ↑in AEL/APL Protect MYC from degradation to promoted
promyelocytes proliferation
[163]
CRNDE ↑in AML cell lines Promote cell proliferation and arrest cell cycle in G0-G1
phase
[168]
MEG3 ↓in AML Promote AML leukemogenesis [172]
CCD26 ↑in NPM1-mutated AML c-Kit Control the growth of AML cells [176]
H19 ↑in AML-M2 patients has-miR-19a/b Regulated the expression of ID2 through competitive
binding to miR-19a/b to increase cells proliferation
[186]
NEAT1 ↓in AML blood sample and AML cell lines miR-23a-3p Increase myeloid cell proliferation and ATRA-induced mye-
loid differentiation, and induce apoptosis
[187]
UCA1 ↑in AML cell lines and CN-AMLwith biallelic
CEBPA
miR-126, RAC1 Increased cell proliferation, inhibited apoptosis, migration,
and invasion by sponging miR-126
[188]
↑in AML cell lines and CN-AML with biallelic
CEBPA
p27kip1 Role in promoting cells proliferation is to sequester hnRNP
I to inhibit the expression of the cell cycle regulator
p27kip1
[167]
↑in HL-60 and HL-60/ADR miR-125a Poor chemotherapy overcome [189]
HOTAIR ↑in de novo AML patients miR-193a;c-Kit Increase AML cells proliferation, inhibited apoptosis and
infiltration of leukemic blasts and number of AML cells
colony formation, and shorten overall survival time
[190]
↑in LSC p15 Promote the self-renewal of leukemia stem cells [191]
CCAT1 ↑in HL60 and AML PB miR-155, c-Myc Upregulated c-Myc expression to increased cells prolifera-
tion and differentiation by its competing endogenous
RNA (ceRNA) activity on miR-155
[192]
FTX ↑in U937 and THP-1 miR-342, ALG3 Drug resistance [193]
PANDAR ↑ANDARLINK Predict adverse prognosis in AML [181]
HOXA-AS2 ↑in APL TRAIL-mediated
pathway
Lead to fine-tuning of apoptosis during ATRA-induced
myeloid differentiation
[194]
↑00PERLINK \l "_ENREF_200" \o "Zhao H,
2013 #197" or><adriamycin-based chemo-
therapy and in U/A and T/A cells
miR-520c-3p/
S100A4 Axis
Knockdown of lncRNA HOXA-AS2 inhibited ADR cell prolif-
eration and chemoresistance of AML by the miR-520c-3p/
S100A4 Axis, and promoted apoptosis
[195]




Regulate myeloid cell differentiation and cell cycle via






IRAN ↑in AML IGF1R long-range DNA interactions [199]
RUNXOR ↑in AML RUNX1 Participate in chromosomal translocation [200]
ANRIL ↑in AML patients at diagnosis




Promote cell survival [201]
vtRNA2-1 Regulate pPKR [202]
linc-223 ↓in AML cell lines IRF4; miR-125-5p Control proliferation and differentiation of AML cells and
IRF4 downregulation by binding miR-125-5p
[203]
LINC00899 ↑INC00899K \l "_ENREF_13patients As a novel serum biomarker for diagnosis and prognosis
of AML
[204]
Abbreviations: CR complete remission, PB peripheral blood, CN-AML cytogenetically normal AML, (U/A) U937/ADR cell, (T/A) THP-1/ADR cell
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miR-125b, all of which targets autophagy-associated
genes, leading to the degradation of oncoprotein
PML-RARA. Moreover, Chen et al. showed that CCAT1
is an oncogenic lncRNA that upregulated c-Myc via its
ceRNA activity on miR-155 to repress monocytic differ-
entiation and promote cell growth [192]. The host
non-coding transcript of miR-223 of linc-223, found
downregulated in AML, is a functional lncRNA which
regulated proliferation and differentiation of AML cells
by binding miR-125-5p [203].
In recent years, the research of circRNAs, as one of
ncRNAs, is focused on their function as “miRNA
sponges” in the complex endogenous RNA networks.
A circRNA HIPK2, for example, sponged miR-124-3p
to regulate the differentiation of all-trans retinoic acid
(ATRA)-induced NB4 cells [155]. Chen et al. [151] re-
ported that circANAPC7 was significantly upregulated
in AML and used an Arraystar human circRNAs
microarray and bioinformatics analysis to predict
when ANAPC7 might bind miR-181 family to partici-
pate in AML pathogenesis. An oncogenic activity of
circRNA was also shown by DLEU2, which was highly
expressed in AML, that inhibited miR-496 expression
to promote cell proliferation and inhibit cell apop-
tosis [157]. A circular RNA 100290, which as an
oncogenic circRNA was upregulated in AML,
showed that it sponged miR-203 to control AML cell
proliferation and apoptosis [152]. Moreover, Shang et
al. demonstrated the circRNA PAN3 controlled AML
chemoresistance by sequestering miR-153-5p and
miR-183-5p, [153]. Moreover, Ping et al. showed that
circ_0009910, upregulated in AML BM and predict-
ing adverse outcome of AML patients, sponged
miR-20a-5p to promote cell proliferation and inhibit
[154].
In combination, lncRNAs and circRNAs introduce a
complex layer in the miRNA target network, respect-
ively, while lncRNA HOTAIRM1 and circ_0009910 can
bind with the same miRNA, miR-20a, to play a different
function in AML. The connections of these three
ncRNAs involved in AML is shown in Fig. 1. But how
lncRNAs and circRNAs compete with each other to bind
with the same miRNAs remains unclear, thus making it
necessary to further explore the relationship between
lncRNAs and circRNAs in AML, to illustrate AML
pathogenesis and therapy.
Fig. 1 The connections of three ncRNAs involved in AML
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Conclusion
ncRNAs are widely recognized as critical participators in
AML pathogenesis. Indeed, specific ncRNA expression
could assist clinicians to classify subtypes, to evaluate
prognosis, and to predict the response of drug treatment
in AML. In this review, we discussed miRNAs, cir-
cRNAs, and lncRNAs, involving in subtypes, molecular
function, chemoresistance and prognosis in AML, and
the interactions between three major ncRNAs. Cur-
rently, the role of miRNAs in AML is most studied, but
the mechanisms of miRNAs in AML still remain com-
plex and unclear owing to miRNAs target genes ranging
from tens to hundreds and involving different signaling
pathways. In recent years, lncRNAs and circRNAs are
introduced into miRNA network one after another and
can be used as ceRNA of miRNAs and miRNAs sponge
to regulate miRNA expression in AML. In our review,
we reported that some lncRNAs such as UCA1 and
linc223 could target the same miRNA, miR-125, to con-
trol proliferation, apoptosis, and differentiation, and
lncRNA HOTAIRM1 participated in autophagy pathway
by binding with miR-125. MiR-125 has been reported to
promote MLL-AF9-driven murine AML by TET2--
VEGFA pathway and target autophagy-associated genes,
leading to the degradation of oncoprotein PML-RARA.
CircRNA_0009910 could also bind miR-20 via compet-
ing with lncRNA HOTAIRM1 to regulate proliferation
and apoptosis. However, whether these three lncRNAs
directly affect MLL-AF9-driven AML and autophagy, the
target genes of miR-20 are not clear. Thus it is import-
ant to find the crossover miRNAs of the three ncRNAs
to help illustrate the connections among these three
ncRNAs. However, currently, there is very little literature
on this subject and the connection networks of the three
ncRNAs are required for further study. Subsequently, we
will also trace relative studies and update the interaction
networks of miRNAs, lncRNAs, and circRNAs.
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